In 2022, the biotech and big health industry had a total output value of 83.62 billion yuan ($11.45 billion), accounting for 47.9 percent of the city's total. This industry has developed a "smart pharmaceutical manufacturing" pattern centered around high-end manufacturing and driven by research and innovation.

[Photo/beijingetown.com.cn]

The area has attracted numerous well-known multinational pharmaceutical companies and innovative pharmaceutical enterprises. Currently, there are more than 4,200 biotech and big health companies in the region, including over 70 enterprises above the designated size, forming a cluster in the biotech and big health industry. These companies span various sectors:

•       High-end pharmaceuticals: Bayer and Youcare Pharmaceutical Group Co Ltd;

•       Biopharmaceuticals: Sanofi and Biotech Pharma;

•       Modern traditional Chinese medicine: Tongrentang and Juxiechang (Beijing) Pharmaceutical Co;

•       New vaccines: Beijing Institute of Biological Products Co Ltd and SinoCellTech;

•       High-end medical equipment: GE Healthcare and Varian;

•       Cell and gene therapy: Immunotech Biopharm Ltd and GenEditBio;

•       Third-party service platforms: Pharmaron Inc and JOINN Laboratories.

In the future, the area will seize further opportunities for profound transformation in the biopharmaceutical field, continuously improve the independent innovation capability and development quality of the entire industry chain, and implement a three-year action plan for the development of the biopharmaceutical industry. It will establish a "1+N" special policy system, plan an 8-square-kilometer core industry aggregation area and expansion areas in Taihu and Jiugong. The goal is to achieve an industrial scale of 200 billion yuan by 2025, creating a global hub for "smart pharmaceutical manufacturing".

[Photo/beijingetown.com.cn]